Validation of BMP8A fibrosis score to identify patients with metabolic dysfunction-associated steatohepatitis with advanced liver fibrosis

Abstract Liver fibrosis represents the main risk factor not only for liver-related but also for overall mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) patients, being metabolic dysfunction-associated steatohepatitis (MASH) its more severe clinical form. We recently dev...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Stephania C. Isaza, Carlos Ernesto Fernández-García, Diego Rojo, Paula Iruzubieta, Javier Ampuero, Rocío Aller, Raquel Vinuesa Campo, Laura Izquierdo-Sánchez, Esther Fuertes-Yebra, Patricia Marañón, Jesús M. Banales, Laura Pagés, Carolina Jiménez-González, Javier Rodríguez de Cía, Irene Olaizola, Judith Gómez-Camarero, Víctor Arroyo-Lopez, Manuel Romero-Gómez, Javier Crespo, Juan M. Pericàs, Carmelo García-Monzón, Águeda González-Rodríguez, on behalf of HEPAmet Registry
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-11-01
coleção:	Biomarker Research
Assuntos:	Advanced liver fibrosis MASLD MASH BMP8A BFS Non-invasive diagnosis
Acesso em linha:	https://doi.org/10.1186/s40364-025-00862-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!